Bibliography
- 1 Mason C, Dunnill P: A brief definition of regenerative medicine. Regen. Med.3(1),1–5 (2008).
- 2 Mason C, Manzotti E: Regen: the industry responsible for cell-based therapies. Regen. Med.4(6),783–785 (2009).
- 3 Lysaght MJ, Crager J: Origins. Tissue Eng. Part A15(7),1449–1450 (2009).
- 4 Mason C: Regenerative medicine 2.0. Regen. Med.2(1),11–18 (2007).
- 5 Mason C: Regenerative medicine. The industry comes of age. Med. Device Technol.18(2),25–30 (2007).
- 6 Helble M: The movement of patients across borders: challenges and opportunities for public health. Bull. World Health Organ.89(1),68–72 (2011).
- 7 Carrera PM, Bridges JF: Globalization and healthcare: understanding health and medical tourism. Expert Rev. Pharmacoecon. Outcomes Res.6(4),447–454 (2006).
- 8 Mason C, Manzotti E: Defeating stem cell tourism. Regen. Med.5(5),681–686 (2010).
- 9 Mason C, Dunnill P: The need for a regen industry voice. Regen. Med.3(5),621–631 (2008).
- 10 Fox LJ: Relief over stem cell lines. Nat. Biotechnol.28,538 (2010).
- 11 Daar AS, Nabel EG, Pramming SK et al.: The global alliance for chronic diseases. Science324(5935),1642 (2009).
- 12 Christensen CM: The Innovator’s Dilemma. Harper Business, NY, USA (2000).
- 13 Ellis H: James Blundell, pioneer of blood transfusion. Br. J. Hosp. Med. (Lond.)68(8),447 (2007).
- 14 Daniels JT, Notara M, Shortt AJ, Secker G, Harris A, Tuft SJ: Limbal epithelial stem cell therapy. Expert Opin. Biol. Ther.7(1),1–3 (2007).
- 15 Evers P: Advances in the Stem Cell Industry. Global Business Insights (2009).
- 16 Mason C, Manzotti E: Regenerative medicine cell therapies: numbers of units manufactured and patients treated between 1988 and 2010. Regen. Med.5(3),307–313 (2010).
- 17 Lichtenberg FR: Despite steep costs, payments for new cancer drugs make economic sense. Nat. Med.17(3),244 (2011).
- 18 Mason C, Manzotti E: The translation cycle: round and round in cycles is the only way forward for regenerative medicine. Regen. Med.5(2),153–155 (2010).
- 19 Irv Weissman. Nat. Biotechnol.29(3),194 (2011).
- 20 Tan PL: Company profile: tissue regeneration for diabetes and neurological diseases at Living Cell Technologies. Regen. Med.5(2),181–187 (2010).
- 21 McKernan R: An audience with Ruth McKernan. Nat. Rev. Drug Discov.8(3),188 (2009).
- 22 McKernan R, McNeish J, Smith D: Pharma’s developing interest in stem cells. Cell Stem Cell6(6),517–520 (2010).
- 23 Van Bokkelen G: Company profile: Athersys. Regen. Med.6(1),39–43 (2011).
- 24 Allison M: Genzyme backs Osiris, despite Prochymal flop. Nat. Biotechnol.27(11),966–967 (2009).
- 25 Cephalon splashes out on mesenchymal stem cells. Nat. Biotechnol.29(2),97 (2011).
- 26 Aggarwal S: What’s fueling the biotech engine – 2009–2010. Nat. Biotechnol.28(11),1165–1171 (2010).
- 101 House of Commons, Bioengineering – Science and Technology Committee Contents: Memorandum submitted by Professor Chris Mason (Bio 31) www.parliament.the-stationery-office.co.uk/pa/cm200910/cmselect/cmsctech/220/10010606.htm
- 102 Alliance for Regenerative Medicine: Membership www.alliancerm.org/members.html
- 103 Biotechnology Industry Organisation: About BIO: Partner to a dynamic industry coming of age www.bio.org/aboutbio/history.asp
- 104 Bloomberg Businessweek. Dendreon’s Provenge extends survival, U.S. Panel says Larkin C www.businessweek.com/news/2010–2011–17/dendreon-s-provenge-extends-survival-u-s-panel-says.html
- 105 Larkin C, Waters R: Bloomberg Dendreon says Provenge may generate $400 million, reports expansion plans www.bloomberg.com/news/2011–2001–07/dendreon-reports-projected-provenge-sales-of-400-million-expansion-plans.html
- 106 Medical News Today: Osiris receives FDA clearance to broaden prochymal expanded access program www.medicalnewstoday.com/articles/135938.php
- 107 Biotechnology Industry Organisation: New study shows the rate of drug approvals lower than previously reported www.bio.org/news/pressreleases/newsitem.asp?id=2011_0214_02
- 108 United States Securities and Exchange Commission (Washington, DC): February 25, 2011. Registration Number 333 – Form S-1 Registration Statement under the Securities Act 1993 – Advanced BioHealing Inc. http://ipo.nasdaq.com/ViewFiling_frames.asp?filename=0001193125%2D11%2D046975%2Etxt&filepath=%5C2011%5C02%5C25%5C
- 109 Dendreon Corporation United States Securities and Exchange Commission (Washington, DC): Form 10-K Annual Report Fiscal year ended 31 December 2010 http://files.shareholder.com/downloads/DNDN/1169714058x0xS950123%2D11%2D20518/1107332/filing.pdf
- 110 Fibrocell Science: Press release March 16th 2011 – Fibrocell Science, Inc. submits final data from histology study to FDA www.fibrocellscience.com/media/2011/2011_03_16.htm
- 111 UK Treasury and Department of Business Innovation and Skills: The plan for growth (page 94) www.hm-treasury.gov.uk/ukecon_growth_index.htm